ImmunityBio

Inducing Immunogenic Cell Death By Orchestrating the Innate (NK) and Adaptive (T Cell) Immune System

Careers

Join our fast-growing immunotherapy company. We offer you the chance to work with a team that is focused on building something impactful.

About Us

ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.

Recent News

Aug. 24, 2020
NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics

Learn more about the science behind COVID-19

Recent News

Aug. 24, 2020
NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics

About Us

ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.

Careers

Join our fast-growing immunotherapy company. We offer you the chance to work with a team that is focused on building something impactful.

Learn more about the science behind COVID-19

Contact Us

ImmunityBio, Inc.

© 2020 ImmunityBio, Inc. All rights reserved.

Privacy | Terms of Use.

© 2020 ImmunityBio, Inc. All rights reserved.

Privacy | Terms of Use.